Novanta Inc. · NASDAQ:NOVT
Novanta — Investor Presentation (June 2021)
14 slides from Novanta's investor presentation, June 2021
Slide 1: A Trusted Technology Partner in Healthcare and Advanced Industrial Markets
A Trusted Technology Partner in Healthcare and Advanced Industrial Markets June 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with business and
Slide 3: Company Overview
Company Overview Leader in Mission Critical Technologies to Medical and Advanced Industrial Markets ~ $650M + $130M + $4.5B annual revenue adjusted EBITDA addressable market ~55% in medical end-markets (+20% of sales) with 5%–7% CAGR Note: The Company neither updates nor confirms 2021 Full Year outl
Slide 4: Novanta Operating Model
Novanta Operating Model DIFFERENTIATED OEM FOCUS ON HIGH PERFORMANCE BUSINESS MODEL CASH RETURNS GROWTH CULTURE Highly engineered “sticky” solutions Disciplined capital allocation based Novanta Growth System based on proprietary technology on ROIC Owner mindset through autonomous Imbedded in ~10-yea
Slide 5: Where We Play and How We Win
Where We Play and How We Win ALIGNED TO HEALTHCARE TRENDS WHERE WE PLAY HOW WE WIN Better outcomes at lower cost Secular growth markets Innovative technologies and sticky OEM customer partnerships Personalized medicine Robotic surgery Proprietary IP with +400 patents Digital health Minimally invasiv
Slide 6: Novanta Operating Groups and Businesses
Novanta Operating Groups and Businesses 40% 40% 20% PHOTONICS VISION PRECISION MOTION DETECTION & ANALYSIS MINIMALLY INVASIVE SURGERY 6 Confidential and Proprietary
Slide 7: Focus on High Growth Applications in Photonics
Focus on High Growth Applications in Photonics Components and subsystems built to deliver precision and performance in demanding applications Digital converting Industrial 4.0 Metals additive Medical Ophthalmology manufacturing “Factory of the future” “Productivity and personalization” • High precis
Slide 8: Leading Technology Provider to Robotic Surgery Applications
Leading Technology Provider to Robotic Surgery Applications PRECISION MOTION SOLUTIONS FOR ROBOTIC SURGERY PRODUCT OFFERING Precision and proprietary technologies Inductive Encoders optimized for the most demanding Optical Encoders applications Motion Control Drives Robotic Joints Precision Motors D
Slide 9: Leading Proprietary Solutions Provider to Endoscopic Surgery
Leading Proprietary Solutions Provider to Endoscopic Surgery EXAMPLE: LAPAROSCOPY AND ARTHROSCOPY Surgical-grade displays (FUTURE: ROBOTIC SURGERY) World leader in fluid and gas management Video couplers - Insufflators with integrated smoke evacuation - Intelligent pumps for arthroscopy Video routin
Slide 10: Intelligent Solutions for Advanced Diagnostics
Intelligent Solutions for Advanced Diagnostics IN VITRO DIAGNOSTICS AND DNA SEQUENCING High-single- Multiple proprietary solutions: light engine sub-system, digit advanced data collection, sample tracking, precision motion Long-term market growth rate Barcode RFID RFID (sample scanning) (reagent tra
Slide 11: Delivering Consistent Financial Results
Delivering Consistent Financial Results ADJUSTED REVENUE ADJUSTED EBITDA FINANCIAL FRAMEWORK ~$650M ~$130M Mid to high single-digit organic growth +13% +13% Double-digit reported CAGR CAGR growth through acquisitions ~55% In Medical End-Markets 100 bps per year of gross margin expansion $225M $42M S
Slide 12: Delivering Innovation Where It Matters Most
Delivering Innovation Where It Matters Most Minimally Invasive Surgery Life Sciences Ophthalmology In Vitro Diagnostics Robotic Surgery Patient Monitoring Surgical Tool Tracking Advanced Industrial Markets 12 Source
Slide 13: Use of Non-GAAP Measures
Use of Non-GAAP Measures The non-GAAP financial measures used in this presentation are non-GAAP Adjusted Revenue and Adjusted EBITDA. The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the Company’s operating performance. I
Slide 14: Non-GAAP Reconciliation
Non-GAAP Reconciliation Three Months (in thousands of dollars) Twelve Months Ended Ended December 31, December 31, December 31, December 31, December 31, December 31, December 31, December 31, December 31, April 2, 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 ADJUSTED REVENUE Revenue (GAAP) $24